Katherine Minichiello

Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non–Small-Cell Lung Cancer Previously Treated With Immunotherapy—Lung-MAP S1800A

Karen L. Reckamp, Mary W. Redman, Konstantin H. Dragnev et al. · Journal of Clinical Oncology · 2022 · 228 citations · Full text

Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol

Mary W. Redman, Vassiliki A. Papadimitrakopoulou, Katherine Minichiello et al. · The Lancet Oncology · 2020 · 114 citations · Full text

Prognostic Biomarkers, Medicine, Biomarker Target +10

Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer

Scott Gettinger, Mary W. Redman, Lyudmila Bazhenova et al. · JAMA Oncology · 2021 · 97 citations · Full text

SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway–Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy)

Charu Aggarwal, Mary W. Redman, Primo N. Lara et al. · Journal of Thoracic Oncology · 2019 · 87 citations

Medicine, Pathology, Phase Ii Study +8

SWOG S1400B (NCT02785913), a Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)

Corey J. Langer, Mary W. Redman, James L. Wade et al. · Journal of Thoracic Oncology · 2019 · 84 citations

Swog S1400b, Medicine, Cancer Management +8